NCI to Conduct Phase 2 Clinical Trial Combining Personalized Neoantigen TCR-T Cell Therapy with Merck's (MRK) Keytruda for Metastatic Cancer
A Clinical Breakthrough in Personalized Neoantigen Targeting
This Phase 2 clinical trial (NCT03412877), led by the U.S. National Cancer Institute (NCI), aims to evaluate the efficacy of a personalized neoantigen-targeting T cell receptor (TCR)-T cell therapy in patients with metastatic solid tumors. Given that existing CAR-T therapies have shown remarkable success in hematological malignancies but face limitations in solid tumors due to the tumor microenvironment and the absence of target antigens, this study is expected to be a significant turning point in the treatment of solid cancers. The NCI's Dr. Steven A. Rosenberg's team is implementing extreme precision medicine by introducing key receptor genes that recognize unique mutations identified through the patient's tumor genomic analysis into the patient's own T cells.
Maximizing Therapeutic Synergy Through Combination with Immune Checkpoint Inhibitors
The most notable aspect of this clinical design is the evaluation of both a single-agent arm and a combination arm with Keytruda (Pembrolizumab), an immune checkpoint inhibitor from Merck & Co. (MRK). Keytruda is an antibody drug that inhibits the PD-1 protein, which is a pathway that cancer cells use to evade immune cells, thereby helping T cells function properly. This combination strategy is adopted to prevent the injected TCR-T cells from being neutralized by the immunosuppressive signals in the tumor microenvironment, even after they penetrate the solid tumor. This can maximize the in vivo persistence and tumor-killing activity of cell therapies, potentially providing tangible therapeutic benefits to patients with refractory metastatic cancers.
A Breakthrough for Patients with Refractory Metastatic Cancers
The clinical trial includes patients with metastatic solid tumors who have not responded to or have developed resistance to standard chemotherapy or existing targeted cancer therapies, leaving them with no further treatment options. This patient population has a short life expectancy and represents an area of extreme unmet medical need, so successful new drug development is likely to lead to accelerated approval. Given that the trial targets a wide range of solid cancers, including non-small cell lung cancer (NSCLC), breast cancer, and gastrointestinal cancers, if clinically meaningful response rates (ORR) are achieved, it is expected to bring about an innovative paradigm shift in cancer treatment.
Changes in the Cell Therapy Market and Industrial Impact
The global TCR-T cell therapy market is estimated to be approximately $360 million to $440 million in 2024-2025 and is projected to grow to approximately $1.2 billion to $1.5 billion by 2034-2035. The results of this NCI clinical trial will be used as direct benchmark data for evaluating the value and attracting investment for the solid cancer pipelines of global biotech companies such as Neogene Therapeutics (acquired by AstraZeneca (AZN)) and Adaptimmune. The public research institution and the pharmaceutical company Merck's drug supply collaboration model will be an important milestone in establishing a production and distribution platform for the commercialization of personalized cell therapies.
The NCI's personalized neoantigen-targeting TCR-T therapy combined with Merck's (MRK) Keytruda (Pembrolizumab) in a Phase 2 clinical trial is a major indicator for verifying the possibility of overcoming the biggest challenge in the field of solid cancer cell therapy: the tumor microenvironment. In the global TCR-T market, which is expected to grow at an annual rate of 13% from approximately $400 million in 2025 to $1.5 billion in 2035, the objective response rate (ORR) data from this trial will be a benchmark for re-evaluating the pipeline value of competitors such as Adaptimmune and AstraZeneca (AZN)-affiliated Neogene. In the short term, the duration of response (DOR) in patients with refractory metastatic cancers who have failed standard treatments will determine whether they can enter the accelerated approval pathway. In the medium to long term, by demonstrating the synergy between personalized gene editing technology and immune checkpoint inhibitors, the optimal combination map for the commercialization of solid cancer immune cell therapies will be completed. Furthermore, the business model that combines the public research capabilities of the U.S. National Cancer Institute (NCI) with clinical support from a major pharmaceutical company provides a development standard for dispersing the initial clinical cost risks of expensive cell therapies.
Source: ClinicalTrials.gov (api_ct)